GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Can Pregnant Patients Receive Stem Cell Therapy?

If you are pregnant, do not proceed with elective stem cell injections on the assumption that they are safe for your baby. Postpone the decision and discuss the exact product with your obstetric clinician. Even Ryoncil, an FDA-approved mesenchymal stromal cell (MSC) product, has no available pregnancy-use data and is not recommended during pregnancy in its prescribing information. Delivery does not automatically make an unproven treatment safe or effective Download.

If you need urgent treatment for cancer or a serious blood disorder, do not delay hospital care because of this advice about elective injections. Your treating specialists and obstetric team need to assess your illness and treatment options together. This article provides general information, not individual treatment clearance.

Can Pregnant Patients Receive Stem Cell Therapy?

Why Elective Injections Should Wait

A clinic’s use of the words “stem cells,” “natural,” or “your own cells” does not establish pregnancy safety. FDA reports harms from unapproved regenerative medicine products, including serious infections, unwanted immune or inflammatory reactions, tumor formation, and reactions at collection or administration sites. These reports concern different products and patients; they do not provide a pregnancy-specific complication rate Important patient and consumer information about regenerative medicine therapies.

Ask about the whole procedure, not just the cells. A proposal may involve collection of fat or bone marrow, an infusion or injection, and additional medicines. Your own cells and donor cells require different questions: how would collection be performed, what medicines would be used, and how would the product be tested? Using donor cells avoids collecting cells from you, but does not itself establish fetal safety.

Hospital Transplants Are a Different Decision

Blood-forming stem cell transplantation is not the same as a private MSC infusion for pain or wellness. Transplants restore blood-forming cells after intensive chemotherapy, sometimes with radiation, for selected cancers and other disorders. NCI describes risks including infection, bleeding, organ damage, infertility, and graft-versus-host disease after donor transplantation Stem cell transplant.

A serious diagnosis during pregnancy calls for coordinated hospital assessment, not a blanket instruction to wait until birth. Ask your hematologist or oncologist and obstetric specialist to discuss the urgency of treatment, gestational age, alternatives, and whether any part of the proposed plan can be deferred. The NCI transplant overview describes general transplant care; it is not evidence that transplantation is safe during pregnancy.

“Do not proceed with an elective clinic injection” does not mean “stop necessary cancer treatment.” Do not stop prescribed treatment or change medicines without speaking with your treating team.

What an Approved MSC Product Actually Shows

Ryoncil (remestemcel-L-rknd) is a donor bone-marrow MSC product. FDA approved it on December 18, 2024, for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. Its approval is not a general authorization for MSC treatment during pregnancy or for unrelated conditions Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.

Question What the evidence says What it means for pregnancy
Did Ryoncil help its studied patients? The single-arm MSB-GVHD001 study included 54 pediatric patients with steroid-refractory acute graft-versus-host disease after transplantation. Overall response at Day 28 was 70% (95% confidence interval 56.4–82.0). Median response duration was 54 days, with a reported range of 7 to 159+ days Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric. This is a disease-response endpoint, not a fetal-safety outcome. There was no randomized comparison group, and these results cannot establish pregnancy safety or benefits for wellness uses.
What does its pregnancy section say? No available data in pregnant women; no animal reproductive or developmental toxicity studies; transfer to the fetus is unknown. The label says Ryoncil is not recommended for pregnant women Download. Approval does not remove the pregnancy evidence gap. These are product-specific findings, not a complete assessment of every cell product.
Does the label establish breastfeeding safety? There is no information about Ryoncil in human milk, effects on the breastfed infant, or effects on milk production. The label calls for weighing breastfeeding benefits, maternal clinical need, and potential adverse effects Download. Neither delivery nor a fixed “pump-and-dump” interval supplies missing safety evidence.

Does Treatment in Japan Change the Answer?

A Japanese clinic’s willingness to accept you is not evidence of fetal safety. PMDA publishes product-specific approvals and review information; an approval for one product and indication does not establish the safety of a different clinic procedure 0004.

Ask for the exact product name and the documents behind any claim of approval or registration. A clinic’s filing is not interchangeable with a product approval and cannot, by itself, demonstrate efficacy or pregnancy safety. When reviewing Japanese registration and compliance documents, separate administrative status from evidence about the proposed treatment. An overview of indications and contraindications is a starting point for questions, not individual medical clearance.

A trial listing also does not establish that a treatment works. Check the actual protocol and ask the study team to confirm eligibility; NCI explains that eligibility depends on the study’s criteria and the patient’s medical information Steps. Do not assume pregnancy or breastfeeding is allowed because a trial appears in a registry.

How to Handle a Clinic Offer While Pregnant

If a clinic offers an elective infusion for joint pain, fatigue, or wellness, ask it to send a written proposal to your obstetric clinician before you pay or arrange travel. Include your gestational age, diagnosis, pregnancy complications, current medicines, and the clinic’s proposed product, cell source, dose, route, collection procedure, and added medicines.

The treatment process, quoted costs, cancellation terms, and arrangements for follow-up if you travel are practical details to obtain in writing. None substitutes for a medical assessment.

  • Ask for pregnancy evidence: Were pregnant patients actually studied with this product, for this condition, by this route? What maternal and infant outcomes were measured, and for how long?
  • Ask what is missing: If the answer relies on animal experiments, nonpregnant adults, testimonials, or registration paperwork, ask the clinician to identify the remaining uncertainty rather than call the treatment safe.
  • Ask about alternatives: What care can address your symptoms now, and what are the consequences of postponing the elective procedure?

This is a preparation scenario, not a report of a treated patient. The Ryoncil example above illustrates a concrete document check: read the pregnancy and lactation sections, not only the approval headline. It does not provide clinical experience with pregnant patients.

If You Already Received an Injection

Tell your obstetric clinician promptly if you received a cell or exosome product before learning you were pregnant. Request the product name, batch details, date, dose, route, and accompanying medicines from the provider. Do not infer either safety or inevitable fetal harm from the exposure alone; ask your clinician what assessment and follow-up are appropriate.

When Can You Reconsider After Birth?

After delivery, reassess whether the treatment has evidence for your condition at all. An unapproved or unproven intervention does not become appropriate simply because pregnancy has ended. If you breastfeed, your clinician should review the specific product and every accompanying medicine; Ryoncil’s label demonstrates why missing lactation data require an individualized discussion Download.

If you plan another pregnancy, ask your treating specialist whether the proposed treatment requires contraception or a waiting interval. No waiting period should be borrowed from a different cell product or drug regimen. For medically necessary transplantation, discuss reproductive plans before treatment where possible: NCI identifies infertility as a potential consequence of intensive transplant treatment Stem cell transplant.

Bottom Line

Postpone elective stem cell injections during pregnancy and ask your obstetric clinician to review the actual proposal. Do not interpret postponement as approval to proceed after birth. Urgent cancer or blood-disorder care requires a separate hospital-led decision; do not delay it because of advice about elective clinic services.

Need the documents for your doctor’s review?

Use the contact form to request treatment information. Your obstetric clinician and treating specialists must assess pregnancy-related decisions; an inquiry is not medical clearance.

Request treatment information